Experimentica Ltd. renews French CIR accreditation

Authors' picture

By Guillaume Demarne on January 22, 2024
Chief Business Officer

Summary: France's Crédit d'Impôt Recherche incentive can cover up to 30% of R&D expenses incurred by innovative French pharma and biotech companies working with Experimentica.

CIR accreditation will translate into a significant financial benefit to Experimentica’s customers in France. This incentive will help bring our expertise to a broader number of companies developing drugs in Ophthalmology.


We are thrilled to announce that Experimentica has successfully renewed its CIR agreement for 2023, 2024, and 2025, reinforcing our commitment to delivering world-class expertise in preclinical assets in Ophthalmology. This renewal marks a significant milestone in our ongoing dedication to supporting the innovative efforts of pharma and biotech companies, especially those in France.

Our continued partnership with the French administration ensures that Experimentica maintains its CIR accreditation, providing valuable financial benefits to our collaborators in this country. This accreditation serves as a testament to the trust and confidence placed in our capabilities by the industry and regulatory authorities alike.

This renewal not only solidifies our position as a premier research partner but also allows us to extend our support to a broader spectrum of companies seeking cutting-edge solutions in Ophthalmology. We are excited about the possibilities that lie ahead and look forward to further contributing to advancements in the field.

For inquiries or to explore the renewed opportunities for collaboration, please reach out to our Chief Business Officer Guillaume Demarne, via email at gd@experimentica.com or by phone at +33 (0) 7 83 55 69 52.

Chief Business Officer